Anges Mg, Inc.

Osaka University

Anges, Inc.

Funpep Co., Ltd.

Other

Daiichi Sankyo Company, Limited

Funpep Inc.

Fujisawa Pharmaceutical Company, Ltd.

Sumitomo Pharmaceuticals Company Limited

Morishita Jintan Co., Ltd.

Bioleaders Corporation

Asubio Pharma Co. Ltd.

Hosokawa Micron Corporation

Medikit Co., Ltd.

Genedesign, Inc.

Ryuichi Morishita

Hironori Nakagami

Akiko Tenma

Toshio Ogihara

Hideki Tomioka

Hiroshi Koriyama

Yasufumi Kaneda

Yoshiaki Taniyama

Motokuni Aoki

Naruto Katsuragi

Munehisa Shimamura

Takashi Miyake

Takefumi Gemba

Nao Tamura

Shintaro Komaba

Ryoko Sata

Akito Maeda

Toshihide Kanamori

Yoshimi Saito

Toshiyuki Chiba

Toshikazu Nakamura

Kazuhiro Maeda

Hitoshi Kotani

Ikuo Kawamura

Takahiro Ochi

Tetsuya Tomita

Fumihiro Sanada

Futoshi Nakagami

Tomio Kawasaki

Kuniaki Nakanishi

Toshio Ogiwara

Takahiro Nakazawa

Mariko Kyutoku

Toshiko Sugimoto

Satoshi Inoue

Hiroaki Matsuda

Hiroaki Nakajima

Takashi Nomura

Hideo Hashimoto

Hideki Mochizuki

Tadashi Tanabe

Mayumi Furuya

Il-Han Lee

Hideki Yoshikawa

Hiroyuki Tsujimoto

Keijiro Sugimura

Yusuke Tsukada

Seiji Yamamoto

Kayoko Kawashima

Yasuo Kunugiza

Natsuki Yoshida

Naruya Tomita

Takeshi Kubo

Tomohiro Kawano

Makoto Mitamura

Kazuya Hiraoka

Tetsuo Miyake

Yoshihumi Kawano

Ryoji Ueki

Ko Hosokawa

Hitomi Kurinami

Shuko Takeda

Kunihiko Takagi

Akane Oyama

Tsuneo Nakajima

Kazuo Oshima

Kaori Hara

Nao Suizu

Makoto Sakaguchi

Junya Azuma

Yohei Bando

Takako Ehara

Hiroshige Nakamura

Akiko Temma

In-Kyu Lee

Hiromi Koike

Kenji Naohara

Yuka Ikeda

Tateki Kubo

Marvin A Tanag

Kenji Yano

Yukihiro Saito

Naoyuki Sato

Provided is a pharmaceutical composition for the treatment of a disease associated with upregulated periostin expression or periostin splice variant switching, which pharmaceutical composition comprises, as an active ingredient, a nucleic acid capable of inducing skipping of exon 17 in periostin gene transcription and/or a nucleic acid capable of inducing skipping of exon 21 in periostin gene transcription. The pharmaceutical composition of the present invention can treat a disease associated with upregulated periostin expression or periostin splice variant switching, while preventing complete inhibition of the functions of periostin.

Pharmaceutical composition for treatment of diseases associated with upregulated periostin expression or periostin splice variant switching

The present invention provides a vaccine containing a complex of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and an epitope of a disease-causing biological protein such as DPP4, IL-17A, IgE, S100A9 or PCSK9, which vaccine uses a less antigenic carrier protein and is capable of inducing antibody production to serve as an effective vaccine.

Conjugate vaccine targeting a disease-causing biological protein

The present invention provides a preventive or therapeutic method for an inflammatory skin disease, such as psoriasis, the method comprising administering an oligopeptide as an active ingredient. More specifically, the invention provides a preventive or therapeutic method for an inflammatory skin disease, the method comprising administering an oligopeptide consisting of an amino acid sequence containing a DE loop sequence of RANKL protein and a &#x3b2;-strand D sequence of RANKL protein placed adjacent to the N-terminal side of the DE loop sequence.

Preventive or therapeutic method for inflammatory skin disease

A cognitive impairment diagnostic apparatus includes: a display which displays a video for diagnosis of cognitive impairment on a display surface; an imaging unit which captures images of an eye of a subject; a detection unit which detects viewpoints of the subject on the display surface in time series based on the images captured by the imaging unit; a creation unit which creates a distribution map representing a distribution of the viewpoints detected by the detection unit; a storage unit which stores case characteristic data indicating a characteristic of a viewpoint distribution corresponding to a typical case in cognitive impairment; and a diagnostic unit which diagnoses cognitive impairment of the subject by determining whether the distribution map has the characteristic indicated by the case characteristic data.

Cognitive impairment diagnostic apparatus and cognitive impairment diagnostic program

Disclosed is a double-stranded oligonucleotide decoy including two transcription factor-binding sites, while keeping its size small. The double-stranded oligonucleotide decoy showing binding affinities for two transcription factors includes a first binding site for a first transcription factor and a second binding site for a second transcription factor. A first strand including the sense strand of the first binding site and a second strand including the sense strand of the second binding site are hybridized to form a double strand in which the sense strand of the first binding site and the sense strand of the second binding site are at least partly hybridized.

Chimeric decoy

The present invention provides a vaccine against IL-17A, which uses, as an immunogen, a polypeptide containing the amino acid sequence shown in SEQ ID NO: 1, or an amino acid sequence derived from a non-human mammal, which corresponds to SEQ ID NO: 1, a prophylactic or therapeutic agent containing the vaccine for diseases involving IL-17A as an aggravation factor, and the like.

Treatment of IL-17A diseases

Provided is an immunogenic composition comprising an antigenic peptide capable of inducing production of a neutralizing antibody against S100A9 and a carrier protein. The immunogenic composition can be used as a highly safe antithrombotic vaccine having antithrombotic effect without a long-term bleeding risk and is useful for the prevention of a disease associated with thrombus formation in which platelet aggregation is involved, particularly for the prevention of recurrent ischemic stroke.

Immunogenic composition targeting S100A9

The present invention provides a combination preparation for inducing a specific immune response to an antigenic peptide, which contains

DNA-peptide combination vaccine

The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of VEGF and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.

DNA vaccine containing VEGF-specific epitope and/or angiopoietin-2-specific epitope

Provided is an oligopeptide having preventive and therapeutic effects on infarction diseases. The oligopeptide contains a DE loop sequence of RANKL protein, and has inhibitory activity on proinflammatory cytokine secretion from cells.

Oligopeptide having proinflammatory cytokine secretion-inhibiting activity

An object of the present invention to discover a short peptide having an anti-aging effect and to provide a novel anti-aging agent comprising the peptide as an active ingredient. The inventors have discovered that a peptide consisting of an amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 1) or a partial sequence thereof and having one or more effects selected from the group consisting of promoting fibroblast growth, promoting hyaluronic acid production and contracting a collagen gel, or a derivative or salt of the peptide is useful as an active ingredient of an anti-aging agent.

Peptide with anti-aging effect and use thereof

The invention provides a peptide and an immunostimulant or hair grower containing the peptide as an active ingredient, as well as a method for hair growth or regrowth promotion by administering an effective amount of the peptide to a mammal. The peptide has 23 or less amino acids and includes the amino acid sequence LHRLKRLRKRL (SEQ ID NO: 1), preferably the amino acid sequence LHRLKRLRKRLK (SEQ ID NO: 9).

Peptide and use thereof

The present invention provides a drug for preventing or treating inflammation-associated diseases in which a periostin isoform having cell adhesion activity is involved, and also provides an inhibitor of a periostin isoform having cell adhesion activity.

Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same

An object of the present invention is to provide a novel peptide and a novel immunostimulant or hair grower containing the peptide as an active ingredient. The present invention provides a peptide of 23 or less amino acids comprising the amino acid sequence LHRLKRLRKRL (SEQ ID NO: 1), preferably the amino acid sequence LHRLKRLRKRLK (SEQ ID NO: 9), and also provides an immunostimulant containing the peptide, a vaccine adjuvant containing the peptide, a vaccine composition containing the peptide, and a hair grower containing the peptide.

Growing community of inventors

Osaka, Japan

Ryuichi Morishita